Stock Events

Stock Events

Pacific Biosciences of California 

€2.06
398
-€0.25-10.68%Friday 16:30

Statistics

Day High
2.21
Day Low
2.2
52W High
2.73
52W Low
1.549
Volume
-
Avg. Volume
-
Mkt Cap
639.38M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

Nov 4Expected
Q2 2026
Q3 2026
-0.12
-0.12
-0.11
-0.11
Expected EPS
-0.11974068224000001
Actual EPS
-0.10680959999999999

Financials

-357.28%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
138.88MRevenue
-496.18MNet Income

Analyst Ratings

$1.90Average Price Target
The highest estimate is ⁦2.28⁩.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
0%
Hold
50%
Sell
50%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow P09.XETRA. It's not an investment recommendation.
Tesla
67
TSLA
Amazon
65
AMZN
Apple
58
AAPL
NVIDIA
57
NVDA

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap35.63B
Illumina offers sequencing and array-based solutions for genetic and genomic analysis, directly competing in the DNA sequencing market with PACB.
Bionano Genomics
BNGO
Mkt Cap16.07M
Bionano Genomics provides optical genome mapping solutions, which compete with PACB's long-read sequencing technologies.
Thermo Fisher Scientific
TMO
Mkt Cap257.71B
Thermo Fisher Scientific offers a range of sequencing and genetic analysis products, competing in the broader genomics space with PACB.
Qiagen NV
QGEN
Mkt Cap10.37B
Qiagen offers sample to insight solutions including sequencing technologies that compete with PACB's offerings.
Intellia Therapeutics
NTLA
Mkt Cap1.75B
Intellia Therapeutics is involved in CRISPR gene editing, a field that relies on accurate DNA sequencing, where PACB's technologies are used.
Editas Medicine
EDIT
Mkt Cap410.06M
Editas Medicine operates in the genome editing space, competing indirectly by relying on sequencing technologies similar to those offered by PACB for its gene editing projects.
CRISPR Therapeutics
CRSP
Mkt Cap4.97B
CRISPR Therapeutics is engaged in gene-based medicine, depending on sequencing technologies where PACB's long-read capabilities are beneficial.
Agenus
AGEN
Mkt Cap308.91M
Agenus is involved in immuno-oncology, a field that increasingly relies on genomic sequencing for personalized medicine, indirectly competing with PACB.
Guardant Health
GH
Mkt Cap23.99B
Guardant Health focuses on liquid biopsies and cancer diagnostics, using sequencing technologies that compete with PACB's offerings in the genomic analysis market.

About

Pacific Biosciences of California Inc is a biotechnology company focused on designing, developing, and manufacturing sequencing solutions that enable scientists and clinical researchers to improve their understanding of the genome and ultimately, resolve genetically complex problems. It operates in, one reportable segment: the development, manufacturing, and marketing of an integrated platform for genetic analysis. The majority of the company's revenue is derived from Americas, followed by Europe Middle East, and Africa and Asia-Pacific.
Show More
CEO
Mark Van Oene
Employees
485
Country
United States
ISIN
US69404D1081
WKN
000A1C3EQ

Listings

MX
MX
PACB.MX
STU
DE
P09.STU
MU
DE
P09.MU
BOATS
BOATS
PACB.BOATS

0 Comments

Share your thoughts

FAQs

What is Pacific Biosciences of California stock price today?▼
The current price of P09.XETRA is €2.06 EUR — it has decreased by -10.68% in the past 24 hours. Watch Pacific Biosciences of California stock price performance more closely on the chart.
What is Pacific Biosciences of California stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on XETRA Stock Exchange exchange Pacific Biosciences of California stocks are traded under the ticker P09.XETRA.
What is Pacific Biosciences of California market cap?▼
Today Pacific Biosciences of California has the market capitalization of 639.38M
When is the next Pacific Biosciences of California earnings date?▼
Pacific Biosciences of California is going to release the next earnings report on February 18, 2027.
What were Pacific Biosciences of California earnings last quarter?▼
P09.XETRA earnings for the last quarter are -0.11 EUR per share, whereas the estimation was -0.12 EUR resulting in a +10.8% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Pacific Biosciences of California revenue for the last year?▼
Pacific Biosciences of California revenue for the last year amounts to 138.88M EUR.
What is Pacific Biosciences of California net income for the last year?▼
P09.XETRA net income for the last year is -496.18M EUR.
How many employees does Pacific Biosciences of California have?▼
As of November 8, 2026, the company has 485 employees.
In which sector is Pacific Biosciences of California located?▼
Pacific Biosciences of California operates in the Health & Wellness sector.
When did Pacific Biosciences of California complete a stock split?▼
Pacific Biosciences of California has not had any recent stock splits.
Where is Pacific Biosciences of California headquartered?▼
Pacific Biosciences of California is headquartered in MENLO PARK, United States.